Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients.


Journal

Journal of pediatric surgery
ISSN: 1531-5037
Titre abrégé: J Pediatr Surg
Pays: United States
ID NLM: 0052631

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 27 02 2018
revised: 16 05 2018
accepted: 13 06 2018
pubmed: 15 7 2018
medline: 21 5 2019
entrez: 15 7 2018
Statut: ppublish

Résumé

Complete metastasectomy is the best predictor of survival in patients with osteosarcoma pulmonary metastases. There has been some controversy in the literature regarding the prognostic significance of the timing of occurrence of lung metastasis. We reviewed the clinical course of all osteosarcoma patients with pulmonary metastases treated by metastasectomy in our hospital from January 2008 through December 2016. Each patient who underwent metastasectomy was placed into one of three groups based on whether lung metastases were present at initial presentation (Group 1), developed during chemotherapy (Group 2), or appeared after completion of chemotherapy (Group 3). Data were obtained retrospectively and follow-up was obtained until the end of June 2017. We identified 170 patients with pulmonary nodules of whom 99 (58.2%) underwent at least one metastasectomy (149 thoracotomies). Eleven patients had benign pulmonary nodules and were excluded. The other 88 patients were classified as Group 1 (37), Group 2 (18) or Group 3 (33). The median follow-up was 35 months (range 8 to 99). Postmetastasis 5-year overall survival (OS) was 38.1 ± 6.4%; event-free survival (EFS) was 25 ± 5.3%. By group, postmetastasis 5-year OS and EFS were 34.3 ± 13% and 18 ± 9.3% in Group 1, 8 ± 6.5% and 6.5 ± 5% in Group 2, and 52 ± 11.4% and 25 ± 9% in Group 3 (P < 0.001). In univariate analysis, the only significant factors associated with survival were timing of occurrence of lung metastasis and the number of lung nodules found. The timing of occurrence of lung metastasis is an important prognostic factor among osteosarcoma patients eligible for metastasectomy. Patients whose metastases occurred during chemotherapy had the worst survival. Level II.

Sections du résumé

BACKGROUND BACKGROUND
Complete metastasectomy is the best predictor of survival in patients with osteosarcoma pulmonary metastases. There has been some controversy in the literature regarding the prognostic significance of the timing of occurrence of lung metastasis.
METHODS METHODS
We reviewed the clinical course of all osteosarcoma patients with pulmonary metastases treated by metastasectomy in our hospital from January 2008 through December 2016. Each patient who underwent metastasectomy was placed into one of three groups based on whether lung metastases were present at initial presentation (Group 1), developed during chemotherapy (Group 2), or appeared after completion of chemotherapy (Group 3). Data were obtained retrospectively and follow-up was obtained until the end of June 2017.
RESULTS RESULTS
We identified 170 patients with pulmonary nodules of whom 99 (58.2%) underwent at least one metastasectomy (149 thoracotomies). Eleven patients had benign pulmonary nodules and were excluded. The other 88 patients were classified as Group 1 (37), Group 2 (18) or Group 3 (33). The median follow-up was 35 months (range 8 to 99). Postmetastasis 5-year overall survival (OS) was 38.1 ± 6.4%; event-free survival (EFS) was 25 ± 5.3%. By group, postmetastasis 5-year OS and EFS were 34.3 ± 13% and 18 ± 9.3% in Group 1, 8 ± 6.5% and 6.5 ± 5% in Group 2, and 52 ± 11.4% and 25 ± 9% in Group 3 (P < 0.001). In univariate analysis, the only significant factors associated with survival were timing of occurrence of lung metastasis and the number of lung nodules found.
CONCLUSION CONCLUSIONS
The timing of occurrence of lung metastasis is an important prognostic factor among osteosarcoma patients eligible for metastasectomy. Patients whose metastases occurred during chemotherapy had the worst survival.
LEVEL OF EVIDENCE METHODS
Level II.

Identifiants

pubmed: 30005831
pii: S0022-3468(18)30394-4
doi: 10.1016/j.jpedsurg.2018.06.019
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

775-779

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Gehad Ahmed (G)

Surgery Department, Faculty of Medicine, Helwan University, Cairo, Egypt; Surgical Oncology Department, Children's Cancer Hospital, Egypt (CCHE), Cairo, Egypt. Electronic address: gehad.taha@gmail.com.

Manal Zamzam (M)

Pediatric Oncology Department, CCHE, Cairo, Egypt; National Cancer Institute, Cairo University, Cairo, Egypt.

Ahmed Kamel (A)

Pediatric Oncology Department, CCHE, Cairo, Egypt; National Cancer Institute, Cairo University, Cairo, Egypt.

Sonia Ahmed (S)

Pediatric Oncology Department, CCHE, Cairo, Egypt; National Cancer Institute, Cairo University, Cairo, Egypt.

Asmaa Salama (A)

Pathology Department, CCHE, Cairo, Egypt; National Cancer Institute, Cairo University, Cairo, Egypt.

Iman Zaki (I)

Radiodiagnosis Department, CCHE, Cairo, Egypt; National Cancer Institute, Cairo University, Cairo, Egypt.

Nehal Kamal (N)

Clinical Research Department, CCHE, Cairo, Egypt.

Maged Elshafiey (M)

Surgical Oncology Department, Children's Cancer Hospital, Egypt (CCHE), Cairo, Egypt; National Cancer Institute, Cairo University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH